Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aptorum Group Ltd Cl A
(NQ:
APM
)
2.990
+0.110 (+3.82%)
Streaming Delayed Price
Updated: 1:50 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptorum Group Ltd Cl A
< Previous
1
2
3
4
5
6
7
Next >
48 Biggest Movers From Yesterday
January 21, 2022
Gainers Aptorum Group Limited (NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company announced it received FDA Orphan Drug designation for...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 20, 2022
Gainers TCR2 Therapeutics (NASDAQ:TCRR) s...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
January 20, 2022
Gainers Aptorum Group (NASDAQ:APM) stock increased by 32.8% to $1.62 during Thursday's regular session. Aptorum Group's stock is trading at a volume of 86.4...
Via
Benzinga
Stocks Roar Back to Life Despite Alarming Jobs Data
January 20, 2022
Stocks are staging a massive comeback today, with the Dow Jones Industrial Average last seen up 428 points midday. Both the S&P 500 Index and Nasdaq Composite are sporting solid midday gains as well.
Via
Talk Markets
Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer
January 20, 2022
The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 20, 2022
Gainers Baudax Bio (NASDAQ:BXRX) stock rose 32.2% to $0.26 during Thursday's pre-market session. The company's market cap stands at $21.9 million. Aptorum Group (...
Via
Benzinga
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
January 20, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
January 18, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
January 10, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
January 10, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
January 10, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
December 03, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
October 19, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S.
October 15, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum To Start Testing SACT-1 In Neuroblastoma Patients
September 15, 2021
The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is...
Via
Benzinga
Exposures
Product Safety
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021
September 15, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
September 15, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate
July 12, 2021
Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus. Specifically,...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 12, 2021
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life...
Via
Benzinga
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
July 12, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
July 09, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group CEO Subscribed Shares In The Company
May 26, 2021
From
Aptorum Group Limited
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 25, 2021
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 43.23% to $2.65 during Tuesday's regular session. As of 12:30 EST, Pieris Pharmaceuticals's...
Via
Benzinga
58 Biggest Movers From Friday
June 21, 2021
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc....
Via
Benzinga
42 Stocks Moving In Tuesday's Mid-Day Session
May 25, 2021
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 28.4% to $10.17 following reports indicating equipment billings increased 50% in April compared to the prior year's...
Via
Benzinga
54 Biggest Movers From Yesterday
May 26, 2021
Gainers Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tuesday after the company reported results for the 13 weeks and the 26 weeks ended...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 24, 2021
Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 101.34% to $12.0 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 17.5...
Via
Benzinga
52 Biggest Movers From Yesterday
May 25, 2021
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,...
Via
Benzinga
Exposures
Product Safety
Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge
May 24, 2021
Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
35 Stocks Moving In Monday's Mid-Day Session
May 24, 2021
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.